Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension

• Status: Recruiting
• Trial end date: 2024-04-30
• Target enrollment: 0
• Participant gender: All

Summary

The primary aim of the study is to assess the antihypertensive efficacy of SPH3127 in patients with mild to moderate essential hypertension.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
• Treatments: Valsartan

Criteria

Inclusion Criteria:

1. Male or female of age ≥18 years;

2. Diagnosed with mild-moderate essential hypertension;

3. Participant has understood the study-required procedures, voluntarily signed informed consent.

Exclusion Criteria:

1. Diagnosed with secondary hypertension, suspected grade 3 hypertension, acute hypertension, or at risk when current antihypertensive therapy discontinued;

2. Suffered by severe heart disease within 6 months;

3. Suffered by severe cerebrovascular disease within 6 months;

4. Suffered by severe or malignant retinopathy;

5. Out of controlled diabetes;

6. History of malignant tumor;

7. History of mental disorder;

8. Subject is planning or in use of other antihypertensive drugs or other drugs may affect blood pressure during the trial;

9. Alcohol or drug abuse;

10. Pregnant, lactating women or subject is planning to pregnant within 6 months after the trial;

11. Assessed by the investigators as unsuitable for participating in the study.